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from day 1 until neutrophil engraftment. GVAX was initiated be-
tween day 30 to 45 if there was adequate hematologic recovery
and no grade II-IV acute GVHD. GVAX was administered ID/SC
qwk 3 doses, then q2wks 3 doses. Taper of tacrolimus began after
vaccine completion. Ten patients (6 URD, 4 MRD) have been trans-
planted to date: 8 AML, 2 MDS/RAEB-2. Seven had circulating
myeloblasts at transplant. GVAX was successfully generated for all 10
patients.Median vaccine cell dose was 1.0 107cells (range, 0.4-1.0
107), and median 24-hr GM-CSF secretion by vaccine cells was 7.25
ng/ml/106cells (range1.0-155.9). Only 4 of 10 patients were able to
start vaccination post transplant. Reasons for failure to initiate vacci-
nation included: death before day 30 (1); acute GVHD (2); insufﬁ-
cient count recovery (3). Among those who receivedGVAX, there was
no GVHD or toxicity attributable to vaccination. Focal inﬁltrates of
lymphocytes were observed in skin biopsies of the vaccination sites.
Two of four vaccinated patients are alive: 1 in CR, and 1 in relapse 5
and 6 months post transplant, respectively. Overall, 7 of 10 patients
have relapsed, 6 before day 100. Although results are preliminary
and the high incidence of early relapse has hindered our ability to
initiate vaccination, GVAX appears to be safe for patients with MDS/
AML after NST. Further cytoreduction prior to NST is necessary for
disease control and improve feasibility of GVAX vaccination in this
very high-risk population.
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TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA
(CML) AND IMATINIB FAILURE AFTER DEVELOPING BCR-ABL KINASE
MUTATIONS WITH ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT)
Jabbour, E., Cortes, J., De Lima, M., Andersson, B., Giralt, S.,
Kantarjian, H., Champlin, R. University of Texas/M.D. Anderson
Cancer Center, Houston, TX.
ASCT is curative for many pts with CML, and may be effective
after imatinib failure. Resistance to imatinib is most often associ-
ated with point mutations in the Bcr-Abl kinase domain. The
outcome of pts with Bcr-Abl kinase mutations after ASCT is not
known. We assessed the outcome of ASCT in 9 pts with CML
(chronic phase [CP]  3, accelerated phase [AP]  3, blast phase
[BP] n  3) harboring 8 different protein kinase mutations. P-loop
mutations were detected in 4 (44%) pts; T315I mutation was
detected in 2 pts (one AP and one CP). Seven male and 2 female
pts, median age of 44 years (range, 26-63 years), received their
ASCT between June 2003 and July 2005. At the time of ASCT,
one pt was in major molecular remission (MMR) (BP, Q252H),
one was in major cytogenetic response (CP, T315I), and 2 were in
complete hematologic response (2 BP, Y253H and E281A). Pre-
parative regimen was busulfan  cyclophosphamide in 7 and ﬂu-
darabine  cyclophosphamide in 2 pts. Donor was fully matched
related in 4 (44%) and unrelated in 5 (56%) pts. Source of stem
cells was peripheral blood and bone marrow in 7 and 2 pts,
respectively. Graft-versus-host disease (GVHD) prophylaxis con-
sisted of tacrolimus and mini methotrexate. All patients engrafted;
there was no treatment-related mortality. Chimerism studies at day
30 and 100 post ASCT were available in 7 pts and were 100% of
donor type. Eight pts achieved a complete molecular remission
(CMR); one pt with a T315I mutation achieved a MMR. Two
(22%) pts (Q252H [BP] and T315I [AP]) relapsed after a median
of 7 months; one of them (T315I) died of disease progression. All
the remaining 7 pts were in CMR for a median of 13 months
(range, 3-20 months). We conclude that ASCT remains an im-
portant salvage option for pts who develop resistance to imatinib
through Bcr-Abl mutations. Early introduction of such strategy
may result in better outcome.
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IN VIVO BIOLUMINESCENCE IMAGING OF ACUTE PROMYELOCYTIC
LEUKEMIA CELL TRAFFICKING AND MOBILIZATION BY AMD3100
Nervi, B.1, Holt, M.1, Rettig, M.P.1, Bridger, G.2, Ley, T.J.1,
DiPersio, J.F.1 1Washington University School of Medicine, St. Louis,
MO; 2AnorMed, Inc., Langley, BC, Canada.
Novel approaches have been developed to mobilize hematopoi-
etic stem cells (HSC) for patients undergoing autologous and allo
transplantation. These strategies may provide insights into im-
proved HSC collection and enhanced egress of leukemic cells and
thus sensitivity to anti-leukemia therapy. CXCR4/SDF-1 axis reg-
ulates the trafﬁcking of normal HSC to and from the bone marrow
(BM). AMD3100 (AMD) speciﬁcally and reversibly blocks SDF-1
binding to CXCR4, and is a promising mobilizing agent currently
in clinical development. We utilized a mouse model of acute
promyelocytic leukemia in which the PML-RAR
 transgene was
knocked into a single allele of the murine cathepsin G locus. We
transduced banked leukemia cells with a dual function reporter
gene that encodes a click beetle red (CBR) luciferase, a biolumi-
nescence imaging (BLI) optical reporter gene, and EGFP for ex
vivo cell sorting (CBR/EGFP). We isolated EGFP cells using a
MoFlo cell sorter, and passaging them in secondary syngeneic
recipients that developed rapidly fatal acute leukemia. Upon intra-
venous (iv) injection of 106 APL cells into syngeneic recipients,
APL rapidly migrated to the BM, with increased BLI signal in the
femurs, spine, ribs, and skull, at 4 days after injection, followed by
spleen inﬁltration and by death due to leukostasis by 14-16 days.
To our knowledge, this represents the only mouse leukemia model
in which leukemia cells home preferentially to the BM in a manner
that is similar to what is seen in human AML. AMD (5 mg/kg) at
the time of APL infusion or bid on days 0-7, had no impact on the
engraftment of either normal HSC or the PML. We observed
rapid mobilization of the APL cells when AMD was administered
11 days after APL injection. 40% of mice that received AMD on
day 11 died 2 to 4 hours after AMD injection as a result of the
rapid and massive mobilization of blasts. Interestingly, CXCR4
expression in mobilized tumor cells decreased from 33  3%
before AMD administration to 19  6%, and 7.8  0.6% after 2
and 12 hours (FACS; P .001). AMD AraC (200 mg/kg) on day
11 prolonged the overall survival of mice, compared with mice
treated only with AraC. In summary, we developed a mouse model
to study the APL cell trafﬁcking, and we have shown leukemia cell
mobilize from the BM into PB after AMD administration. In these
preliminary results we observed that AMD may sensitize APL cells
to AraC. We propose that CXCR4/SDF-1 is a key regulator for
leukemia migration and homing to the BM.
LYMPHOMA/MULTIPLE MYELOMA
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POSITIVE POSITRON EMISSION TOMOGRAPHY (PET) PRE-AUTOLO-
GOUS STEM CELL TRANSPLANT (ASCT) IN NON-HODGKIN LYMPHOMA
(NHL) DOES NOT PRECLUDE SUCCESSFUL OUTCOME
Bondly, C.C.1, Johnston, P.B.1, Lowe, V.J.2, Ansell, S.M.1,
Inwards, D.J.1, Porrata, L.F.1, Micallef, I.N.1 1Mayo Clinic College of
Medicine, Department of Internal Medicine, Division of Hematology/
Blood & Marrow Transplantation, Rochester, MN; 2Mayo Clinic College
of Medicine, Department of Radiology, Division of Nuclear Medicine,
Rochester, MN.
PET has become an important imaging modality for lymphoma,
and has been reported to be of prognostic signiﬁcance prior to
ASCT for NHL.Methods: To assess the prognostic value of PET
prior to ASCT in NHL, PET pre and post ASCT was prospec-
tively obtained in all NHL patients. From May 2003 to December
2004, 100 patients underwent ASCT for NHL. PET was consid-
ered positive if it had abnormal FDG uptake; CT was positive if it
had areas of lymphadenopathy as deﬁned by the international
response criteria. Results: Median age was 58 (range 17-74); 69%
were male. Patients had received a median of 2 prior chemotherapy
regimens (range 1-9). At relapse, prior to ASCT, the median IPI
was 2 (range 1-5); 31% of patients were stage I or II; 69% were
stage III or IV. Histology included DLBCL 50, transformed NHL
15, mantle cell NHL 11, low-grade NHL 8, T-cell NHL 6,
primary CNS NHL 5, and high grade NHL 5. At ASCT, 43
patients were in CR, 49 in PR, 3 in untreated relapse, and 5 had
resistant disease. The conditioning regimen was BEAM in 89;
Zevalin/BEAM in 10. Pre-ASCT PET was not obtained in 8
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